OLUMIANT — Total revenues
Incyte OLUMIANT — Total revenues decreased by 15.7% to $36.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 18.2%, from $30.80M to $36.40M. Over 4 years (FY 2021 to FY 2025), OLUMIANT — Total revenues shows a downward trend with a -10.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market adoption or successful commercialization, while a decrease may signal increased competition, patent expiration, or loss of market share.
Detailed definition
This metric represents the total gross revenue recognized from the sale or licensing of a specific pharmaceutical produc...
Peer comparison
Comparable to product-specific revenue reporting in other biopharmaceutical firms, often benchmarked against therapeutic area peers.
incy_segment_olumiant_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $55.23M | $55.23M | $55.23M | $0.00 | $70.00M | $0.00 | $64.50M | $34.20M | $32.00M | $29.60M | $40.30M | $30.60M | $31.70M | $34.80M | $38.50M | $30.80M | $33.50M | $37.10M | $43.20M | $36.40M |
| QoQ Change | — | +0.0% | +0.0% | -100.0% | — | -100.0% | — | -47.0% | -6.4% | -7.5% | +36.1% | -24.1% | +3.6% | +9.8% | +10.6% | -20.0% | +8.8% | +10.7% | +16.4% | -15.7% |
| YoY Change | — | — | — | — | +26.8% | -100.0% | +16.8% | — | -54.3% | — | -37.5% | -10.5% | -0.9% | +17.6% | -4.5% | +0.7% | +5.7% | +6.6% | +12.2% | +18.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Incyte's olumiant — total revenues?
- Incyte (INCY) reported olumiant — total revenues of $36.40M in Q1 2026.
- How has Incyte's olumiant — total revenues changed year-over-year?
- Incyte's olumiant — total revenues increased by 18.2% year-over-year, from $30.80M to $36.40M.
- What is the long-term trend for Incyte's olumiant — total revenues?
- Over 4 years (2021 to 2025), Incyte's olumiant — total revenues has grown at a -10.1% compound annual growth rate (CAGR), from $220.90M to $144.60M.
- What does olumiant — total revenues mean?
- The total sales revenue generated by a specific drug product.